These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 1801634)
21. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans. Cryz SJ; Sadoff JC; Cross AS; Fürer E Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836 [No Abstract] [Full Text] [Related]
22. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219 [TBL] [Abstract][Full Text] [Related]
23. Opsonic defect in patients with cystic fibrosis of the pancreas. Biggar WD; Holmes B; Good RA Proc Natl Acad Sci U S A; 1971 Aug; 68(8):1716-9. PubMed ID: 5001942 [TBL] [Abstract][Full Text] [Related]
24. IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis. Cordon SM; Elborn JS; Rayner RJ; Hiller EJ; Shale DJ Arch Dis Child; 1992 Jun; 67(6):737-40. PubMed ID: 1626995 [TBL] [Abstract][Full Text] [Related]
25. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review. Mauch RM; Levy CE J Cyst Fibros; 2014 Sep; 13(5):499-507. PubMed ID: 24522086 [TBL] [Abstract][Full Text] [Related]
26. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Pier GB Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760 [TBL] [Abstract][Full Text] [Related]
27. Different serological examinations in cystic fibrosis patients: response to Pseudomonas aeruginosa St-Ag. Magni A; Trancassini M; Giordano A; De Vito D; Cimino G; Quattrucci S; Antonelli M; Cipriani P New Microbiol; 1997 Oct; 20(4):295-302. PubMed ID: 9385598 [TBL] [Abstract][Full Text] [Related]
28. [Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. IV. The effect of immunization with Pseudomonas aeruginosa vaccine on the immune status of volunteer donors]. Titova TI; Sidorova TN; Radkevich SA; Antsiferova NG; Moroz AF Zh Mikrobiol Epidemiol Immunobiol; 1985 Aug; (8):80-4. PubMed ID: 3933225 [TBL] [Abstract][Full Text] [Related]
29. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346 [TBL] [Abstract][Full Text] [Related]
30. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa. Pier GB; Thomas DM J Infect Dis; 1983 Aug; 148(2):206-13. PubMed ID: 6411830 [TBL] [Abstract][Full Text] [Related]
31. IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection. Pressler T; Pedersen SS; Espersen F; Høiby N; Koch C Pediatr Pulmonol; 1992 Sep; 14(1):44-51. PubMed ID: 1437343 [TBL] [Abstract][Full Text] [Related]
32. [Immunoenzyme analysis method for detecting anti-Pseudomonas aeruginosa antibodies in persons inoculated with pyoimmunogen]. Severtsova MK; Vaĭda MB; Varró R Zh Mikrobiol Epidemiol Immunobiol; 1985 Jan; (1):55-9. PubMed ID: 3920846 [TBL] [Abstract][Full Text] [Related]
33. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Cryz SJ; Sadoff JC; Ohman D; Fürer E J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471 [TBL] [Abstract][Full Text] [Related]
34. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330 [TBL] [Abstract][Full Text] [Related]
35. Whole cell heat-killed gram-negative bacilli vaccine. Waisbren BA; Martins RR; Bruns WT; Kurzynski TA Wis Med J; 1974 Apr; 73(4):S42-5. PubMed ID: 4206996 [No Abstract] [Full Text] [Related]
36. Enzyme-linked immunosorbent assay antibody responses to a temperature-sensitive mutant of Pseudomonas aeruginosa. Sordelli DO; Rojas RA; Cerquetti MC; Hooke AM; Degnan PJ; Bellanti JA Infect Immun; 1985 Oct; 50(1):324-7. PubMed ID: 3930404 [TBL] [Abstract][Full Text] [Related]
37. Antibody to multiple mucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis, measured by an enzyme-linked immunosorbent assay. Baltimore RS; Fick RB; Fino L Pediatr Res; 1986 Nov; 20(11):1085-90. PubMed ID: 3099248 [TBL] [Abstract][Full Text] [Related]
38. The role of complement in the opsonization of mucoid and non-mucoid strains of Pseudomonas aeruginosa. Baltimore RS; Shedd DG Pediatr Res; 1983 Dec; 17(12):952-8. PubMed ID: 6419197 [TBL] [Abstract][Full Text] [Related]
39. Determination of type specific IgG Pseudomonas antibodies by the ELISA test after administration of the anti Pseudomonas aeruginosa vaccine. Meitert T; Meitert E; Pencu E; Tonciu M Arch Roum Pathol Exp Microbiol; 1984; 43(1):53-60. PubMed ID: 6442132 [No Abstract] [Full Text] [Related]
40. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis. Buret A; Cripps AW Am Rev Respir Dis; 1993 Sep; 148(3):793-805. PubMed ID: 8368651 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]